Merus discovers and develops innovative therapeutic human antibodies with improved clinical efficacy based on its single light chain (sLC) antibody technologies
Single light chain (sLC) antibodies share a common immunoglobulin light chain while retaining the exquisite specificity and high affinity of antibodies with diversified light chains. Multiple sLC human antibodies against different epitopes/targets are efficiently co-expressed in a single manufacturing cell to generate novel antibody formats like full length IgG bispecific antibodies and mixtures of IgG antibodies (Oligoclonics™). By combining multiple mechanisms of action, these formats provide the basis for enhanced disease-modifying targeted therapies.
Based on these technologies Merus is building a pipeline of innovative therapeutic antibodies with improved clinical efficacy in multiple therapeutic areas.